AHRO-001: Completed Phase I enrollment

AtheroNova said its partner OOO CardioNova, a subsidiary of Maxwell Biotech, completed enrollment of about 54 healthy volunteers in a double-blind, placebo-controlled, Russian Phase I trial evaluating...